Thrombotic Risk and Cardiovascular Events in Patients With Revascularization Deferral After Fractional Flow Reserve Assessment

Yasutsugu Shiono(Imperial College London), Nobuhiro Tanaka(Tokyo Medical University Hachioji Medical Center), Nobuhiro Suematsu(Saiseikai Fukuoka General Hospital), Akiko Matsuo(Japanese Red Cross Society Kyoto Daini Hospital), Tairo Kurita(Mie University), Tatsuya Saigusa(Shinshu University), Kenji Yaginuma(Juntendo University Urayasu Hospital), Yuetsu Kikuta(Imperial College London), Kenichi Tsujita(Kumamoto University), Fumitoshi Toyota(Fukuoka Hospital), Tatsuki Doijiri(Seiwa Hospital), Hidenobu Terai(Kanazawa Hospital), Shoichi Kuramitsu(Kokura Memorial Hospital), Tomohiro Sakamoto(Saiseikai Kumamoto Hospital), Taku Asano(Amsterdam UMC Location University of Amsterdam), Ken Harada(Ibaraki University), Takayuki Ishihara(Kansai Rosai Hospital), Manabu Ogita(Juntendo University Shizuoka Hospital), Kazunori Horie(Sendai Kousei Hospital), Hitoshi Matsuo, Hiroyoshi Yokoi(Kurume University), Atsushi Tanaka(Teikyo University), Hiroaki Takashima(Aichi Medical University), Katsuhiko Masamura(Nakamura Memorial Hospital), Shinjo Sonoda(University of Occupational and Environmental Health Japan)
JACC: Cardiovascular Interventions
February 1, 2022
10.1016/j.jcin.2021.11.020
Cited by 8

Related Papers

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI
|JAMA|2019|848
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
|The Lancet|2018|793
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
|Circulation Journal|2019|582
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2015|453
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
|New England Journal of Medicine|2024|410